



VANTAGE WIRE PUBLISHES REPORT ON PACIFIC THERAPEUTICS PARTNER VODIS INNOVATIVE PHARMACEUTICALS

VANCOUVER, BC, Canada – September 2, 2014 – Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the “Company”) is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company’s lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are \$1 billion plus market opportunities.

Vantagewire.com has published a report highlighting the joint venture between the Company and Vodis Innovative Pharmaceuticals (CSE: VP, Frankfurt: 1JV). The article titled **“Whether Recreational or Medicinal, Only The Finest Marijuana Will Do”** can be accessed at

<http://www.vantagewire.com/2014/08/whether-recreational-or-medicinal-only-the-finest-marijuana-will-do/>

The article explains, “Pacific Therapeutics will use extracts from Vodis’ high quality marijuana strains to develop therapies in line with its mandate to reformulate approved drugs to increase efficacy and patient compliance, while reducing side effects. Current applications address fibrosis as well as erectile dysfunction; both high margin, high growth fields. In addition to the \$1.1 billion Pulmonary Fibrosis market opportunity, Pacific’s PTL-202 may be effective as a treatment for Liver Cirrhosis a \$1.56 billion global market opportunity in 2010, that is expected to grow to \$2.03 billion by 2017 (Global Data, Feb, 2011).”

ABOUT PACIFIC THERAPEUTICS LTD.

The Company’s strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.

Pacific Therapeutics Ltd. lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of an FDA approved drug and an amino acid and an extremely potent and important antioxidant. The Company has completed an initial clinical trial of the combination with positive results.

“It’s estimated that 45 % of all deaths are related to fibrotic changes” World Health Organization Feb, 2008.

409 Granville Street Suite 1500, Vancouver, BC V6C 1T2
Ph: (604) 738-1049 Fax: (604) 738-1094

Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK are forecast to rise to over \$1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.

ABOUT VODIS PHARMACEUTICALS

Vodis is one of Canada's foremost brand names in the medical marijuana business. Its products have consistently won or placed at each competition they have entered. Vodis is in the application process to become a Licensed Producer at its 12,000 square foot facility in Canada and is currently preparing to break ground in Washington State at a 25,000 square foot commercial production facility.

For further information visit our website at www.pacifictherapeutics.com or email us at doug.unwin@pacifictherapeutics.com

Douglas H. Unwin, CEO & President
(604) 738-1049
doug.unwin@pacifictherapeutics.com

FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.